Aytu BioPharma Inc./$AYTU
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
Ticker
$AYTU
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
-
ISIN
US0547548588
Website
AYTU Metrics
BasicAdvanced
$21M
-
-$0.83
0.05
-
Price and volume
Market cap
$21M
Beta
0.05
52-week high
$2.70
52-week low
$0.95
Average daily volume
522K
Financial strength
Current ratio
1.026
Quick ratio
0.764
Long term debt to equity
30.191
Total debt to equity
64.54
Interest coverage (TTM)
-0.30%
Profitability
EBITDA (TTM)
6
Gross margin (TTM)
64.77%
Net profit margin (TTM)
2.01%
Operating margin (TTM)
-1.45%
Effective tax rate (TTM)
-86.96%
Management effectiveness
Return on assets (TTM)
-0.59%
Return on equity (TTM)
-3.06%
Valuation
Price to revenue (TTM)
0.168
Price to book
0.4
Price to tangible book (TTM)
-1.02
Price to free cash flow (TTM)
-2.389
Free cash flow yield (TTM)
-41.85%
Free cash flow per share (TTM)
-95.84%
Growth
Revenue change (TTM)
0.41%
Earnings per share change (TTM)
-68.66%
3-year revenue growth (CAGR)
-4.14%
10-year revenue growth (CAGR)
95.30%
3-year earnings per share growth (CAGR)
-78.60%
AYTU News
AllArticlesVideos
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
Accesswire·1 week ago
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
Accesswire·2 weeks ago
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aytu BioPharma Inc. stock?
Aytu BioPharma Inc. (AYTU) has a market cap of $21M as of July 04, 2025.
What is the P/E ratio for Aytu BioPharma Inc. stock?
The price to earnings (P/E) ratio for Aytu BioPharma Inc. (AYTU) stock is 0 as of July 04, 2025.
Does Aytu BioPharma Inc. stock pay dividends?
No, Aytu BioPharma Inc. (AYTU) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Aytu BioPharma Inc. dividend payment date?
Aytu BioPharma Inc. (AYTU) stock does not pay dividends to its shareholders.
What is the beta indicator for Aytu BioPharma Inc.?
Aytu BioPharma Inc. (AYTU) has a beta rating of 0.05. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.